Supreme Court of the United States to Hear Isolated DNA Patent Case
"Two previous decisions by the
About Genetic Patents and Genetic Testing
The BRACAnalysis test detects the presence of the BRCA1 and BRCA2 genetic mutations that can help determine a patient's risk of breast and ovarian cancer and inform treatment options. Women who test positive using Myriad's BRACAnalysis have an 82 percent higher risk of developing breast cancer and a 44 percent higher risk of ovarian cancer in their lifetimes. The test is widely available for all women with a family history of cancer and is cost effective for both patients and the healthcare system. Approximately one million women have already benefited from taking the BRACAnalysis test.
Myriad supports research studies on BRCA1, BRCA2 and other genes. More than 18,000 scientists have studied the BRCAgenes and published more than 9,000 research papers, making these genes among the most widely researched genes in history. In addition, Myriad has facilitated research through a partnership with the
Health economic studies conclude that Myriad's genetic tests are fairly priced. Excerpts supporting this conclusion include the following:
- A study published in Genetics In Medicine noted, "Prices for BRCA1 and 2 testing do not reflect an obvious price premium attributable to exclusive patent rights…"
An Advisory Committee report to the Secretary of
Health and Human Servicesstated, "…the per-unit price of the full-sequenced BRCA test, which often is cited as being priced very high, was actually quite comparable to the price of full-sequenced tests done on colon cancer, for which associated patents are nonexclusively licensed."
Additionally, Myriad has also established a
Even though Myriad automatically retests all positive results to confirm the findings at no additional charge to the patient, second-opinion testing is also available for all patients. Since 1999, many laboratories have performed confirmatory and second-opinion testing. The NCBI Genetic Testing Registry lists seven laboratories in
About Myriad's Patent Landscape
Myriad's intellectual property for its BRACAnalysis® test is strong, with 24 issued patents and more than 500 claims. This provides Myriad with extensive patent protection through 2018.
Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, OnDose, Panexia and Prolaris are trademarks or registered trademarks of
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential impact this case and appeal will have on Myriad and its operations, as well as industry as a whole; the length and degree of the Company's patent protection through 2018; the success of Myriad in defending this case and appeal before the
CONTACT: Media Contact:Source:
Stephanie Ashe Continuum Health Communications(650) 245-0425 firstname.lastname@example.org Investor Contact: Jim EvansChief Financial Officer (801) 584-3672 email@example.com
News Provided by Acquire Media